Herein, we reported a bioengineered exosome drug delivery nanoplatform (Apatinib-ExoaPD-L1), in which HEK293T-derived exosomes were surface functionalized with anti-PD-L1 antibody (aPD-L1) and encapsulated the tyrosine kinase inhibitor Apatinib, aiming to enhance the tumor-targeted immunotherapy against CRC. The gene discussed is CD274; the disease is colorectal carcinoma.